AXSM

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.

Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.